The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
Rs. 40 cr buyback, 200% dividend announced
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
The deal signals a clear push to expand access to care in underserved regions
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
Subscribe To Our Newsletter & Stay Updated
